Tech Company Financing Transactions
DeuterOncology Funding Round
On 1/19/2023, DeuterOncology landed $6.1 million in Series A investment from InvestSud, Newton Biocapital and Noshaq.
Transaction Overview
Company Name
Announced On
1/19/2023
Transaction Type
Venture Equity
Amount
$6,140,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to start the phase I clinical study for its lead product DO-2, an improved MET kinase inhibitor currently being developed as a potential best-in-class targeted therapy for lung cancer.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Clos Chanmurly 13
Liege, 4000
Belgium
Liege, 4000
Belgium
Phone
Undisclosed
Website
Email Address
Overview
DeuterOncology NV was founded in September 2020 by? Dr Timothy Perera and is based in Liege in Belgium. The company generated pre-clinical validation of DO-2, a novel, highly selective, brain penetrant deuterated MET kinase and RAS pathway inhibitor. Timothy Perera was the originator of the initial idea for the use of deuteration as a means to modulate metabolic properties of the parent drug and remains a strong champion of this exciting new molecule. The molecule was in-licensed (worldwide rights outside of greater China) from OCTIMET Oncology NV and originally licensed from Janssen Pharmaceutica in 2017.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Timothy Perera
Chief Financial Officer
Tomas Dyck
Chief Medical Officer
Jaap Verweij
Browse more venture capital transactions:
Prev: 1/19/2023: Ulvetanna venture capital transaction
Next: 1/19/2023: Higharc venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs